These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28574239)

  • 1. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
    Health Resources and Services Administration, HHS
    Fed Regist; 2017 May; 82(96):22893-5. PubMed ID: 28574239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
    Health Resources and Services Administration, HHS
    Fed Regist; 2017 Sep; 82(188):45511-4. PubMed ID: 28990743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
    Health Resources and Services Administration, Department of Health and Human Services (HHS)
    Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
    Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using 340B drug discounts to provide a financially sustainable medication discharge service.
    Wu T; Williams C; Vranek K; Mattingly TJ
    Res Social Adm Pharm; 2019 Jan; 15(1):114-116. PubMed ID: 29606609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notice regarding Section 602 of the Veterans Health Care Act of 1992; new drug pricing--PHS. Final notice.
    Fed Regist; 1995 Oct; 60(190):51488-9. PubMed ID: 10151188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 8. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 9. Final notice regarding section 602 of the Veterans Health Care Act of 1992 entity guidelines--PHS. Final notice.
    Fed Regist; 1994 May; 59(92):25110-4. PubMed ID: 10134125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Feb; 69(35):8105-7. PubMed ID: 14997866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exclusion of orphan drugs for certain covered entities under 340B Program. Final rule.
    Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS)
    Fed Regist; 2013 Jul; 78(141):44016-28. PubMed ID: 23882725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare program; manufacturer submission of manufacturer's average sales price (ASP) data for Medicare Part B drugs and biologicals. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2004 Sep; 69(179):55763-5. PubMed ID: 15372731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notice regarding section 602 of the Veterans Health Care Act of 1992--rebate option--HRSA. Final notice.
    Fed Regist; 1998 Jun; 63(124):35239-42. PubMed ID: 10180635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
    Conti RM; Nikpay SS; Buntin MB
    JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final notice regarding section 602 of the Veterans Health Care Act of 1992 duplicate discounts and rebates on drug purchases--HRSA. Final notice.
    Fed Regist; 1993 Jun; 58(119):34058-9. PubMed ID: 10126861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Reach of the 340B Drug Pricing Program.
    Albrecht J; Mudahar S
    JAMA Dermatol; 2015 Sep; 151(9):923-4. PubMed ID: 25993384
    [No Abstract]   [Full Text] [Related]  

  • 17. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
    Dickson S
    JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
    Zeta LM
    Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare program; manufacturer submission of manufacturer's average sales price (ASP) data for Medicare Part B drugs and biologicals. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2004 Apr; 69(66):17935-41. PubMed ID: 15068020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notice regarding section 602 of the Veterans Health Care Act of 1992 rebate option--HRSA. Notice.
    Fed Regist; 1997 Aug; 62(168):45823-4. PubMed ID: 10169845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.